The AlphaLISA™ CTLA-4/CD80 binding kit is designed for the detection of binding activity between human CTLA-4 and CD80, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.
Feature | Specification |
---|---|
Application | Protein-Protein Interaction |
Sample Volume | 10 µL |
The AlphaLISA™ CTLA-4/CD80 binding kit is designed for the detection of binding activity between human CTLA-4 and CD80, using a fast and simple homogeneous AlphaLISA assay (no wash steps). This assay can be used to screen for small molecules that inhibit binding, as a competitive ligand binding (CLB) assay to screen therapeutic blocking antibodies, and for potency assays.
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a biotinylated CD80 binds to the Streptavidin-coated Alpha Donor beads, while His tagged CTLA-4 is captured by Anti-His AlphaLISA Acceptor beads. When CD80 binding to CTLA-4 happens, Donor beads and Acceptor beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Human Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of differentiation 152), is a cell membrane receptor and a member of immunoglobulin superfamily. CTLA-4 is expressed once a T cell becomes active and modulates T cell signals by blocking the CD80 (B7.1) and CD86 (B7.2) ligands from binding to CD28. CTLA-4, functioning as an immune checkpoint, downregulates T cell immune responses. Because of its profound inhibitory role blocking CTLA-4 and CD80 or CD86 binding has been considered as promising therapeutic target for human autoimmune disease and cancers.
Application |
Protein-Protein Interaction
|
---|---|
Automation Compatible |
Yes
|
Brand |
AlphaLISA
|
Detection Modality |
Alpha
|
Product Group |
Kit
|
Sample Volume |
10 µL
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
CTLA4,CD80
|
Target Class |
Binding Assay
|
Target Species |
Human
|
Technology |
Alpha
|
Therapeutic Area |
Immuno-oncology
|
Unit Size |
500 assay points
|
Are you looking for resources, click on the resource type to explore further.
A single White Paper for a review of immuno-oncology
Immuno-oncology, the field which stimulates a individual's own immunity in...
Advance your autoimmune disease research and benefit from Revvity broad offering of reagent technologies
Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...
We are here to answer your questions.